Lloyd E Damon
Affiliation: University of California
- Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphomaL Damon
Division of Hematology Oncology, University of California, San Francisco, CA 94143 0324, USA
Bone Marrow Transplant 42:649-57. 2008..The equalization of EFS and superiority of OS in patients intensely mobilized to those nonintensely mobilized suggests that a treatment strategy using intensive chemotherapy for mobilization may be improving NHL outcomes after ASCT...
- Mobilization of hematopoietic stem cells into the peripheral bloodLloyd E Damon
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143 0324, USA
Expert Rev Hematol 2:717-33. 2009..Patients failing to mobilize adequate hematopoietic stem cells with myeloid growth factors can often be successfully mobilized with chemotherapy plus myeloid growth factors or with plerixafor and granulocyte colony-stimulating factor...
- Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide scheduleLloyd E Damon
Division of Hematology Oncology, University of California, San Francisco, 400 Parnassus Avenue, Box 0324, San Francisco, CA 94143, USA
Cancer Chemother Pharmacol 53:468-74. 2004..The differences in toxicity of etoposide following continuous or bolus infusion are unknown...
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909Lloyd E Damon
University of California Medical Center, The Helen Diller Comprehensive Cancer Center, 400 Parnassus Ave, San Francisco, CA 94143 0324, USA
J Clin Oncol 27:6101-8. 2009..The incorporation of rituximab with aggressive chemotherapy and ASCT may be responsible for the encouraging outcomes demonstrated in this study, which produced results comparable to similar treatment regimens...
- Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastimLloyd Damon
University of California, San Francisco, San Francisco, California 94143 0324, USA
Biol Blood Marrow Transplant 12:316-24. 2006....
- Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remissionGabriel N Mannis
a Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
Leuk Lymphoma 57:1560-6. 2016..AutoHCT therefore remains a reasonable option for intermediate-risk patients with AML in CR1. ..
- High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancerUzair B Chaudhary
UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
Am J Clin Oncol 28:130-7. 2005..A significant correlation was seen between intended carboplatin dose and actual AUC. TVCa high-dose chemotherapy is active and well tolerated in patients with relapsed or refractory germ cell cancer...
- Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paragangliomaSara Gonias
Department of Pediatrics, University of California, San Francisco, 350 Parnassus Ave, Suite 710, San Francisco, CA 94117, USA
J Clin Oncol 27:4162-8. 2009..To evaluate the safety and efficacy of high-dose [(131)I]metaiodobenzylguanidine ([(131)I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL)...
- Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell TransplantationGabriel N Mannis
Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
Biol Blood Marrow Transplant 22:1030-6. 2016..8; confidence interval, 1.8 to 312.9; P = .0158). Our findings suggest that NGS for MRD detection can predict long-term RFS in patients undergoing autoHCT for high-risk ALL. ..
- Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRIMatthew J Wieduwilt
Division of Hematology Oncology, University of California San Francisco, Box 1270, 505 Parnassus Avenue, San Francisco, CA 94143, USA
Clin Cancer Res 18:1146-55. 2012..In addition, we evaluated the prognostic value of the minimum apparent diffusion coefficient (ADC(min)) derived from diffusion-weighted MRI (DW-MRI) in patients treated with this regimen...
- Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemiaCharles Linker
Bone Marrow Transplant Program, Medical Center, University of California San Francisco, 400 Parnassus Avenue, Rm A502, San Francisco, CA 94143 0324, USA
J Clin Oncol 20:2464-71. 2002..To assess the efficacy and toxicity of a new treatment program of intensified and shortened cyclical chemotherapy (protocol 8707) in adults with acute lymphoblastic leukemia (ALL)...
- Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartmentJames L Rubenstein
Division of Hematology Oncology, Comprehensive Cancer Center, Cancer Research Institute, Department of Neurosurgery, UCSF, San Francisco, CA 94143, USA
Blood 101:466-8. 2003..96 hours. A phase 1 study to investigate the safety and pharmacokinetics of intrathecal rituximab in patients with recurrent lymphomatous meningitis will be implemented based on these findings...
- Pandemic (H1N1) 2009 infection in patients with hematologic malignancyCatherine Liu
University of California, San Francisco, Division of Infectious Diseases, California 94143 0654, USA
Emerg Infect Dis 16:1910-7. 2010..Rigorous infection control, improved techniques for diagnosing respiratory disease, and early antiviral therapy can prevent nosocomial transmission and optimize patient care...
- Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)Paul A Fitzgerald
Department of Medicine, UCSF Comprehensive Cancer Center, Box 1222, University of California, San Francisco, San Francisco, CA 94143 1222, USA
Ann N Y Acad Sci 1073:465-90. 2006..For patients with metastatic PHEO or PGL, who have good *I-MIBG uptake on diagnostic scanning, high-dose 131I-MIBG therapy was effective in producing a sustained CR, PR, or SD in 67% of patients, with tolerable toxicity...
- Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphomaJames L Rubenstein
Division of Hematology Oncology, and the Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94143, USA
J Clin Oncol 25:1350-6. 2007..We therefore conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL)...
- A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemiaGabriel N Mannis
Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA
Clin Lymphoma Myeloma Leuk 15:377-83. 2015..We designed a dose-escalation study to examine the maximum tolerated dose (MTD) of targeted I.V. busulfan with bolus etoposide as preparative therapy for autologous HSCT in AML...
- Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphomaJames L Rubenstein
Division of Hematology Oncology and Helen Diller Comprehensive Cancer Center, University of California San Francisco, CA 94143, USA
Blood 121:745-51. 2013..We conclude that intraventricular rituximab in combination with MTX is feasible and highly active in the treatment of drug-resistant CNS NHL that is refractory or unresponsive to IV rituximab...
- High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemiaNathan Gunn
Department of Medicine, Division of Hematology Oncology, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
Biol Blood Marrow Transplant 9:643-8. 2003..0 versus 9.8 units; P =.01). Our findings suggest that CD34+ cell doses >10 x 10(6)/kg CD34+ result in faster engraftment and fewer red blood cell and platelet transfusions...
- Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemiaGarth Beinart
Department of Hematology Oncology, University of California San Francisco, San Francisco, California, USA
Am J Hematol 77:331-5. 2004..This results in a specificity of 90% and a relative risk of 10 (P = 0.014). Therefore, a fibrinogen <50 mg/dL may serve as a marker for a hypercoagulable state in ALL patients receiving L-asparaginase...
- Non-Hodgkin's lymphomasAndrew D Zelenetz
J Natl Compr Canc Netw 6:356-421. 2008